Planned
There are currently no planned studies in our center.
Ongoing
There are currently no ongoing studies in our center.
Closed
AARDVARC D8731C00002
A Phase 2, open-label, study to assess the efficacy, safety and tolerability of AZD4635 in combination with durvalumab and the combination of AZD4635 with cabazitaxel and durvalumab in patients who have progressive metastatic castrate resistant prostate cancer
- Principal investigator : Prof. Dr. H. Dumez
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT04495179
CARD LPS14201
A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
- Principal investigator : Prof. Dr. H. Dumez
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT02485691
MEDIVATION MDV3800-06
A Phase 2, Open-label, 2-arm, Response Rate Study Of Talazoparib In Men With Dna Repair Defects And Metastatic Castration-resistant Prostate Cancer Who Previously Received Taxane-based Chemotherapy And Progressed On At Least 1 Novel Hormonal Agent (Enzalutamide And/or Abiraterone Acetate/Prednisone)
- Principal investigator : Prof. Dr. H. Dumez
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03148795
VISION PSMA617-01
An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Principal investigator : Prof. Dr. Benoit Beuselinck
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03511664